citalopram has been researched along with Addiction, Opioid in 3 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pain is common among opioid-dependent patients, yet pharmacologic strategies are limited." | 6.76 | Escitalopram is associated with reductions in pain severity and pain interference in opioid dependent patients with depressive symptoms. ( Anderson, BJ; Herman, DS; Kettavong, M; Stein, MD; Tsui, JI, 2011) |
| "Pain is common among opioid-dependent patients, yet pharmacologic strategies are limited." | 2.76 | Escitalopram is associated with reductions in pain severity and pain interference in opioid dependent patients with depressive symptoms. ( Anderson, BJ; Herman, DS; Kettavong, M; Stein, MD; Tsui, JI, 2011) |
| " Treatment dropout was defined as missing seven consecutive buprenorphine dosing days." | 2.75 | Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. ( Anderson, BJ; Cioe, PA; Friedmann, PD; Herman, DS; Kettavong, M; Stein, MD; Tellioglu, T, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stein, MD | 3 |
| Herman, DS | 3 |
| Kettavong, M | 2 |
| Cioe, PA | 1 |
| Friedmann, PD | 1 |
| Tellioglu, T | 1 |
| Anderson, BJ | 3 |
| Tsui, JI | 1 |
| Strong, DR | 1 |
| Brown, RA | 1 |
| Sims, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Antidepressants During Office-Based Buprenorphine[NCT00475878] | Phase 3 | 147 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Depressive symptoms, as measured by self-report during study interviews, using the Beck Depression Inventory II. Scores ranged from 0-63; higher scores indicate more depressive symptoms. (NCT00475878)
Timeframe: 3 months
| Intervention | units on a scale (Mean) |
|---|---|
| 10 mg Escitalopram | 12.31 |
| Placebo | 11.35 |
Drop-out is defined as 7 or more days of missed Buprenorphine doses (NCT00475878)
Timeframe: 3 months
| Intervention | percentage of participants (Number) |
|---|---|
| 10 mg Escitalopram | 33.3 |
| Placebo | 44.0 |
3 trials available for citalopram and Addiction, Opioid
| Article | Year |
|---|---|
Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons.
Topics: Adult; Antidepressive Agents; Buprenorphine; Citalopram; Depression; Double-Blind Method; Female; Hu | 2010 |
Escitalopram is associated with reductions in pain severity and pain interference in opioid dependent patients with depressive symptoms.
Topics: Adult; Analgesics, Opioid; Antidepressive Agents, Second-Generation; Citalopram; Depression; Female; | 2011 |
Persistence on a stress-challenge task before initiating buprenorphine treatment was associated with successful transition from opioid use to early abstinence.
Topics: Adult; Antidepressive Agents, Second-Generation; Buprenorphine; Citalopram; Comorbidity; Depressive | 2012 |